Arquerdx

Develops urine-based immunoassay tests for genitourinary cancers.

placeSunderland, England, United Kingdom calendar_todayFounded 2007 groups9 employees language arquerdx.com

Registered entities

Investor mix

86 investors on record; lead investors include North East Fund.

Investor typeCountShare
Venture capital56%
Private equity22%
Angel & family office11%
Bank & private debt11%
Other / undisclosed7790%
Coming soon